VivoSeq
Respiratory

Rhinitis

29

Pipeline Programs↗

6

Active Trials↗

15

Companies Involved↗

Rhinitis is an emerging landscape with 29 programs across 15 companies. The most active players are Novartis, Vitae Pharmaceuticals Inc., an Allergan affiliate, Pfizer. 12 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

31/100

Completion Rate

79/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2S

Salix

1 program

Phase 3Sanofi logo

Sanofi

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

37 of 38 classified programs — the dominant modality here.

3%ALL OTHERSMonoclonal antibody13%

Small molecule leads; the ring shows all 38 classified programs, each share of the total. Modality classified for 100% of 45 pipeline programs.

Analysis

Trial Status

42

clinical trials

Completed27 · 64%
Recruiting5 · 12%
Withdrawn4 · 10%
Unknown status2 · 5%
Terminated2 · 5%
Suspended1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

42 trials

Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis
Recruiting·EEndeavor Health·Phase 4·NCT05626621·81 enrolled
Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis
Recruiting·—·N/A·NCT05348148·450 enrolled
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
Recruiting·—·Phase 3·NCT07348302·736 enrolled
Posterior Nasal Nerve Combined with Anterior Ethmoid Neurotomy for Idiopathic Rhinitis
Recruiting·—·N/A·NCT06870292·150 enrolled
Clinical Study on the Treatment of Rhinitis Sicca With Sodium Hyaluronate Adjustable Nasal Irrigator
Recruiting·—·Phase 4·NCT07308015·200 enrolled
Washed Microbiota Transplantation for Rhinitis
Not yet recruiting·TThe Second Hospital of Nanjing Medical University·N/A·NCT06350448·40 enrolled
Grass Pollen Immunotherapy Using a Cluster Regime for Seasonal Rhinitis and Asthma
Completed·IImperial College London·Phase 3·NCT00135642·44 enrolled
Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis
Completed·AAche Laboratorios Farmaceuticos S.A.·Phase 3·NCT01393548·879 enrolled
The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine
Completed·KKyung Hee University Hospital at Gangdong·Phase 4·NCT02477293·40 enrolled
A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers
Completed·BBioHealth Technologies Inc.·Phase 4·NCT02225912
Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis
Completed·AALK-Abelló A/S·Phase 3·NCT01603056·617 enrolled
Cleanoze® Irrigation Device With Powder Preparation Versus Conventional Irrigation Method for Chronic Rhinitis
Completed·KKhon Kaen University·Phase 3·NCT02763241·115 enrolled
The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
Completed·VVirginia Commonwealth University·Phase 2·NCT01364467·30 enrolled
Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®
Completed·AALK-Abelló A/S·Phase 4·NCT02437786·58 enrolled
Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis
Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT02288156·80 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)